Current problems in cardiology · 2025
Metabolic syndrome, ischemic heart disease, and heart failure: insights from the Colombian Heart Failure Registry (RECOLFACA).
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mejía Miguel Álvarez, Cárdenas Sofía López, Echeverría Luis Eduardo, Rivera-Toquica Alex, Gómez-Mesa Juan Esteban, Gutiérrez Clara Inés Saldarriaga, Estupiñán Juan Fernando Carvajal, Santos Claudia Victoria Anchique, Herazo Jannes Buelvas, Luna Paula, Peña Ángel Alberto García
Аннотация
BACKGROUND: Ischemic heart disease (IHD) is still a leading cause of morbidity and mortality worldwide, with major implications for healthcare systems, especially in low- and middle-income countries. Effective metabolic control and risk factor management, including evidence-based pharmacological therapies such as statins, ACE inhibitors (ACEIs), and angiotensin receptor-neprilysin inhibitors (ARNIs), are essential for reducing adverse outcomes. However, gaps persist in the implementation of these therapies, particularly in resource-limited regions.
OBJECTIVE: To evaluate metabolic control and the use of evidence-based therapies in patients with IHD enrolled in the Colombian Heart Failure Registry (RECOLFACA), and to identify barriers to optimal treatment implementation.
METHODS: This cross-sectional study analyzed demographic, clinical, and biochemical data, as well as medication usage, from patients with confirmed IHD. Descriptive and inferential statistical analyses were performed to identify treatment patterns and associated factors.
RESULTS: Among 2,528 patients with heart failure (HF), 1,123 had IHD. Statins were prescribed to 73.6% (827), antiplatelets to 66.3% (745), and ARNIs to only 10.1% (114), despite guideline recommendations. Statin use was notably low among patients with chronic kidney disease (CKD) (18.1%), diabetes mellitus type 2 (15.8%), and both conditions combined (3.2%).
CONCLUSIONS: Despite robust evidence supporting their efficacy, the use of statins, ACEIs, and ARNIs remains suboptimal in Colombia. Addressing barriers to access, adherence, and healthcare delivery is crucial to improve outcomes and align clinical practices with international standards. These findings highlight the need for targeted interventions and future studies to evaluate strategies that enhance access to and adherence with guideline-directed therapies.
OBJECTIVE: To evaluate metabolic control and the use of evidence-based therapies in patients with IHD enrolled in the Colombian Heart Failure Registry (RECOLFACA), and to identify barriers to optimal treatment implementation.
METHODS: This cross-sectional study analyzed demographic, clinical, and biochemical data, as well as medication usage, from patients with confirmed IHD. Descriptive and inferential statistical analyses were performed to identify treatment patterns and associated factors.
RESULTS: Among 2,528 patients with heart failure (HF), 1,123 had IHD. Statins were prescribed to 73.6% (827), antiplatelets to 66.3% (745), and ARNIs to only 10.1% (114), despite guideline recommendations. Statin use was notably low among patients with chronic kidney disease (CKD) (18.1%), diabetes mellitus type 2 (15.8%), and both conditions combined (3.2%).
CONCLUSIONS: Despite robust evidence supporting their efficacy, the use of statins, ACEIs, and ARNIs remains suboptimal in Colombia. Addressing barriers to access, adherence, and healthcare delivery is crucial to improve outcomes and align clinical practices with international standards. These findings highlight the need for targeted interventions and future studies to evaluate strategies that enhance access to and adherence with guideline-directed therapies.